Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

52P - Chemotherapy selection in routine clinical practice in Japan for HER2-negative advanced or metastatic breast cancer (KBCRN A001: E-SPEC Study)


22 Nov 2020


e-Poster Display Session


Cytotoxic Therapy;  Targeted Therapy

Tumour Site

Breast Cancer


Yookija Kang


Annals of Oncology (2020) 31 (suppl_6): S1257-S1269. 10.1016/annonc/annonc353


Y. Kang1, Y. Kikawa2, T. Kotake3, S. Tsuyuki1, S. Takahara4, H. Yamashiro5, H. Yoshibayashi6, M. Takada7, R. Yasuoka8, K. Yamagami9, H. Suwa10, T. Okuno11, I. Nakayama12, T. Kato13, Y. Moriguchi14, H. Ishiguro15, T. Kagimura16, T. Taguchi8, T. Sugie2, M. Toi17

Author affiliations

  • 1 Department Of Breast Surgery, Osaka Red Cross Hospital, 543-8555 - Osaka/JP
  • 2 Department Of Breast Surgery, Kansai Medical University, 573-1191 - Hirakata/JP
  • 3 Medical Oncology, kansai Electric Power Hospital, 553-0003 - Osaka/JP
  • 4 Department Of Breast Surgery, Tazuke Kofukai Medical Research Institute, Kitano Hospital, 530-8480 - Osaka/JP
  • 5 Department Of Breast Surgery, Tenri Hospital, 632-8552 - Nara/JP
  • 6 Department Of Breast Surgery, Japanese Red CrossWakayama Medical Center, 6408558 - Wakayama/JP
  • 7 Breast Surgery Department, Kyoto University Hospital, 606-8507 - Kyoto/JP
  • 8 Department Of Endocrine And Breast Surgery, Kyoto Prefectural University of Medicine, 602-8566 - Kyoto/JP
  • 9 Department Of Breast Surgery, Shinko Hospital, 651-0072 - Hyogo/JP
  • 10 Department Of Breast Surgery, Hyogo Prefectural Amagasaki General Medical Center, 660-8550 - Hyogo/JP
  • 11 Department Of Breast Surgery, Kobe City Nishi-Kobe Medical Center, 651-2273 - Hyogo/JP
  • 12 Department Of Breast Surgery, Kyoto Min-iren Chuo Hospital, 616-8147 - Kyoto/JP
  • 13 Department Of Breast Surgery, Yamato Takada Municipal Hospital, 635-8501 - Nara/JP
  • 14 Department Of Breast Surgery, Kyoto City Hospital, 604-8845 - Kyoto/JP
  • 15 Medical Oncology, International University of Health and Welfare Hospital, 286-8520 - Chiba/JP
  • 16 Translational Research Center For Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe, 650-0047 - Hyogo/JP
  • 17 Breast Surgery Department, Kyoto University Hospital, Kyoto/JP


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 52P


Anthracycline-based (A) and taxane-based (T) chemotherapy (ChT) are standards of care for triple-negative (TN) or hormone-resistant advanced/metastatic breast cancer (AMBC) in 1st- or 2nd-line ChT. However, the choice of regimen for oncologists and patients is diverse, requiring consideration of not only survival benefit but also quality of life issues. We reported that most patients received eribulin (E) in 1st- or 2nd- line therapy in the Japanese real-world setting at the ESMO 2018 congress. Here, we report updated data regarding ChT sequences and treatment discontinuation.


We prospectively registered TN AMBC patients and estrogen receptor-positive and HER2-negative AMBC patients who relapsed during or within 6 months after the end of adjuvant endocrine therapy (ET) and were refractory to at least one previous ET. Patterns of ChT and their feasibility were evaluated (ClinicalTrials.gov No. NCT02551263).


Between June 2015 and July 2017, a total of 201 patients were enrolled, 180 of whom were analyzed. The frequent 1st- and 2nd-line ChT sequences were as follows: T followed by E (n=33), oral FU-based therapy (FU) followed by E (n=26), E followed by T (n=21), T followed by FU (n=11), and E followed by FU (n=10). E was administered in 1st- or 2nd-line therapy for 60 patients who did not receive A, and for 35 patients who did not receive T. The main reason the attending physician chose E for patients who did not receive A was “reducing toxicity” in 38.3%, “non-life threatening” in 30.0%, and “patient preference” in 18.3%. Respective ratios in patients who did not receive T were 34.3%, 34.3%, and 20.0%. Patients treated with E or FU in 1st- and 2nd-line ChT had significantly less discontinuation due to adverse events than those with A/T (1st line: p=0.011, 2nd-line: p=0.036). In contrast, there was no statistical difference between E/FU and A/T in 3rd-line ChT (p=1.000).


This study showed that various 1st- and 2nd-sequence treatments including E were chosen in a real-world setting. The lower proportion of adverse events and lower discontinuation rate of E/FU in 1st- and 2nd-line therapy may be due to the better feasibility of these treatments.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Kyoto Breast Cancer Research Network.


Eisai Co., Ltd.


T. Kagimura: Research grant/Funding (self): Eisai. T. Taguchi: Honoraria (self), Donation: Eisai. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.